CING
Cingulate Inc.3.8700
-0.2800-6.75%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
26.15MP/E (TTM)
-Basic EPS (TTM)
-2.77Dividend Yield
0%Recent Filings
8-K
8-K
Cingulate funds ADHD launch prep
Cingulate Inc. secured $6 million in net proceeds from an unsecured promissory note issued to Avondale Capital on November 7, 2025, carrying 9% annual interest and maturing in 18 months, to fund working capital amid FDA review of its ADHD drug CTx-1301. The company simultaneously appointed industry veteran Bryan Downey as Chief Commercial Officer to spearhead launch preparations, extending cash runway into Q2 2026 pending May 31, 2026 PDUFA approval. Downey's expertise bolsters commercialization efforts. Yet default risks could spike interest to 22%.
8-K
FDA accepts Cingulate's ADHD NDA
Cingulate Inc. announced on October 14, 2025, that the FDA accepted its NDA for CTx-1301, a once-daily dexmethylphenidate for ADHD in children and adults, under the 505(b)(2) pathway, with a PDUFA target of May 31, 2026. Phase 3 trials showed rapid onset, sustained efficacy, and a safety profile matching other methylphenidate products, addressing gaps in current therapies. FDA acceptance validates the submission's completeness. Commercial preparations advance amid approval risks.
8-K
Debt conversion via stock issuance
Cingulate Inc. issued 325,729 shares of common stock in five tranches from July 30 to September 5, 2025, converting portions of lender debt at prices ranging from $3.79 to $5.16 per share, exempt under Section 3(a)(9) of the Securities Act. This debt-for-equity swap reduces immediate liabilities while diluting existing shareholders. Total value reached approximately $1.3 million. No further details on remaining debt disclosed.
8-K
Leadership changes at Cingulate
Cingulate Inc. appointed John A. Roberts as Executive Chairman on August 14, 2025, placing CEO Shane Schaffer on administrative leave with his salary cut to 75%. Laurie Myers' employment ended August 7, 2025, triggering a $436,720 separation payment over 12 months, full vesting of unvested options, and ongoing noncompete covenants. Leadership shakeup signals internal shifts. Yet stability hinges on swift resolution.
ADIL
Adial Pharmaceuticals, Inc
0.26-0.01
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
COYA
Coya Therapeutics, Inc.
5.83-0.08
CYBN
Cybin Inc.
6.66+0.00
LBRX
LB Pharmaceuticals Inc
19.82-0.04
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12